Mereo BioPharma Group plc
MREO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $518 | $305 | $90 | $187 |
| - Cash | $70 | $57 | $56 | $94 |
| + Debt | $6 | $6 | $13 | $17 |
| Enterprise Value | $454 | $253 | $47 | $109 |
| Revenue | $0 | $10 | $0 | $49 |
| % Growth | -100% | – | -100% | – |
| Gross Profit | $0 | $7 | $0 | $25 |
| % Margin | – | 74.3% | – | 50.9% |
| EBITDA | -$41 | -$26 | -$40 | $25 |
| % Margin | – | -260.6% | – | 51.8% |
| Net Income | -$43 | -$29 | -$42 | $17 |
| % Margin | – | -294.7% | – | 34.9% |
| EPS Diluted | -0.29 | -1,100.22 | -1,750.35 | 749.65 |
| % Growth | 100% | 37.1% | -333.5% | – |
| Operating Cash Flow | -$33 | -$21 | -$49 | -$7 |
| Capital Expenditures | -$1 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$34 | -$22 | -$49 | -$8 |